Vaderis Therapeutics is a clinical-stage biopharmaceutical company developing engasertib, a once-daily oral therapy for hereditary hemorrhagic telangiectasia (HHT).
The company is transitioning into pivotal-stage development with initiation of the global Phase 3 HEROIC study evaluating engasertib in patients with moderate-to-severe HHT.